SUMMARY
INTRODUCTION
The frequent clustering of arterial hypertension, diabetes and obesity is potentially aggravated by factors such as old age, smoking, alcohol consumption, sedentary lifestyle, among others. Chronic sleep deprivation occurs in various endocrine-metabolic disorders further aggravating a cascade of harmful effects A recent review suggests that sleep disturbance and long sleep duration, but not short sleep duration, are associated with increases in markers of systemic inflammation 3 . Evidence suggests that sleep deprivation induces harmful effects on metabolic abnormalities, in the hypothalamic-pituitary-adrenal axis, and ORIGINAL ARTICLE ultimately weight gain 4 , In fact, an explanation for the biological changes found in patients with short or long sleep duration remains obscure. For instance, in healthy adults, sleep deprivation is associated with cognitive, neurophysiologic and endocrine changes, despite increased regional brain activity. These apparently paradoxical findings may be explained by adaptive behaviour or a compensatory effect 5 . The adipose tissue secretes several bioactive molecules, known as adipokines that are influential to whole-body homeostasis and serve as a measure of adipose tissue activity 6 . Adiponectin is the most abundant adipocytokine and has a regulatory effect on the metabolism of glucose and lipid 7, 8 . High adiponectin levels have been associated with positive cardiovascular benefits; whereas low values of adiponectin are connected to obesity, metabolic syndrome, type 2 diabetes and dyslipidaemia
9
. Previously, female diabetic showed higher adiponectin levels than male indicating a gender effect 10. Furthermore, higher adiponectin levels are inversely related to body weight and to insulin resistance
10
. All this evidence indicates that a complex set of variables influence adiponectin concentration.
The objective of the present study is to investigate factors influencing adiponectin expression in a population with endocrine-metabolic disorders.
METHODS

Study design and patients
This is a cross sectional evaluation of 332 patients with endocrine-metabolic disorders. We consecutively recruited patients from an outpatient clinic at Centro Integrado de Diabetes e Hipertensão (CIDH) in Fortaleza, Brazil. Initially, 400 subjects from the central database were examined. Sixty-eight were excluded due to difficulty of posterior examination (N=34), severe associated comorbidities (N=23) or refusal to participate in the study (N=11). Three-hundred and thirty-two of them attended the eligible criteria for the desired analyses. Plasma adiponectin levels were obtained in a subsample of 120 patients. The study involved individuals of both genders, aged from 18 to 80 years old, with a Body Mass Index (BMI) from 18.5-45.0 kg/m 2 . All patients underwent clinical evaluation, investigation of comorbid disorders and blood tests. None had severe heart disease, renal insufficiency, stroke, dementia, severe depression, gastrointestinal and/or liver dysfunction or previous diagnosis of cancer. In this study, patients with type 1 diabetes and/or on use of insulin or glucocorticoids were not included. The local Research Ethics Committee (HUWC-CEP 031-04-09) approved the protocol and all included patients provided written informed consent.
Assessments
Three previously trained health workers assessed demographic and clinical information using a face-toface interview. Endocrine-metabolic disorders were investigated. Arterial hypertension was defined as a systolic blood pressure ≥140mm Hg, diastolic blood pressure ≥90mm Hg, and/or current use of antihypertensive medications
11
. American Diabetic Association (ADA) classification rated patients as normal, with glucose intolerance or diabetes. The presence of a fastening ≥126mg/dl, post-prandial glucose concentration ≥200mg/dl, or diabetes symptoms and a plasmatic glucose concentration (last mealtime independent) ≥200mg/dl defined diabetes
12
. Intermediate plasma glucose levels situated between those considered normal and those considered diabetic characterized impaired glucose tolerance. A fasting blood glucose level of above 6.0 mmol/L or a blood glucose level of over 7.8 mmol/L 2 hours after consuming 75g of glucose established impaired glucose tolerance. Overweight was considered if Body Mass Index (BMI) ≥25 kg/m 2 and obesity if BMI ≥30 kg/m 2 . Hyperlipidaemia was defined as an alteration in lipid profile, in which the Low Density Cholesterol (LDL) ≥100mg/dl, High Density Cholesterol (HDL) <40mg/ dl and/or triglycerides >150mg/dl
13
. Chart review confirmed the clinical information.
Questionnaires investigated sleep duration, physical exercise and comorbidities. Patients were questioned about how many hours of sleep they usually get during the week and during the weekend. Less than six hours of sleep per day occurring at least four days per week defined the presence of chronic sleep deprivation. Less than 30 minutes of exercise per day and/ or the absence of heavy physical exertion at home or at work, namely cleaning, hand washing clothes or other defined physical inactivity.
Biochemical analyses
Blood sampling and laboratory measurements were obtained in all patients. Samples were taken for biochemical investigations in blood collection tubes (Vacutainer -Vacuum II ®). Blood was drawn from an antecubital vein with the participants in a sitting po-sition and was collected between 7:00 am and 9:30 AM, without stasis; the serum was separated after centrifugation for 10 minutes and stored at -70 degrees Celsius for the analyses. Adiponectin levels were determined by ELISA using commercial kits (Kit Assay Designs Cortisol ELISA, Michigan, USA®). , p=0.007). Table 1 depicts general characteristics of patients in the entire group of patients and according to the presence of chronic insufficient sleep (<6h). Reduced sleep time tended to be more frequent in patients with reduced glucose tolerance (ADA classification, p=0.05).
Statistical analysis
In this population, adiponectin levels were inversely to sagittal abdominal diameter (Pearson Exact Test: r=-0.176, p=0.04) and to fasting insulin levels (Pearson Exact Test: r=-0.226, p=0.008) ( Figure 1A and 1B). Adiponectin levels were higher in patients with chronic sleep deprivation (4.2±2.7) than in those without (2.5±2.0) (Students' t test, p=0.001) (Figure 2 Table 2) .
DISCUSSION
This study shows that in patients with endocrine metabolic disorders, adiponectin levels are higher in older patients and are negatively related to sagittal abdominal diameter and fasting insulin. These findings are in agreement with previous reports demonstrating higher adiponectin levels with increasing age in both genders, regardless of the presence of obesity
14
. The role of increased adiponectin with increasing age is unclear. Kizer et al. suggest that age-related homeostatic dysregulation explains high adiponectin levels over time in long-lived adults. These higher values have been associated with greater physical disability and mortality
15
. Previous studies confirm that adiposity is negatively related to adiponectin levels 16, 17 . In this work, only sagittal abdominal diameter was inversely related to adiponectin concentration indicating that this measure is a reliable predictor of visceral adiposity
18,19
. Similar to our findings, high fasting insulin was associated with lower levels of adiponectin. More precisely, increased resistin has been associated with lower adiponectin
20
. Our findings confirm that low values of adiponectin are connected to adiposity and high fasting insulin.
Presently, sleep deprivation was independently associated with elevated adiponectin levels. We hypothesize that the latter findings can be explained by a compensatory mechanism to limit the harmful effects of sleep deprivation. In agreement, a counter-regulatory effect mitigating further damage was previously suggested
21
. To the best of our knowledge, to date, no study reported a relationship between chronic sleep deprivation and adiponectin levels in a population with endocrine-metabolic disorder. Previous studies relating adiponectin levels with chronic sleep alterations show controversial results. In healthy young volunteers, Robertson et al. described no changes of adiponectin levels after three weeks of reduced daily sleep duration
. Simpson et al. reported differential effects according to gender and ethnicity
22
. Taheri et al. described, in a population of recruited volunteers, no change in adiponectin levels . In obese subjects, plasma low adiponectin level was associated with obstructive sleep apnea
25
. In partial agreement with the latter study, low adiponectin levels, increased levels of inflammatory markers, and atherogenic lipid profiles were found in association with obstructive sleep apnoea in hypertensive patients 26 . In opposition to the previous studies, an increase of adiponectin levels was associated with sleep apnea 25, 27 Furthermore, adiponectin also shows a circadian pattern 28 . Regrettably, in the present work, sleep apnoea and circadian rhythm were not investigated. Together, all this evidence indicates that adiponectin levels are influenced by a range of factors.
In this study, patients with diabetes tended to have more sleep deprivation. Both, short and long sleep duration, and poor glucose control are reported in patients with type 2 diabetes
29,30
. In our study, no gender effect was found
23
. In opposition to our findings, higher levels of adiponectin were found in women 31, 32 . In hypertensive patients, gender and renal function influenced adiponectin levels
21
. Interestingly, in this population, adiponectin measures did not correlate with anthropometric measures or to Gamma-glutamyltransferase (GGT) measures. Hsieh et al. showed that low serum adiponectin level may precipitate hepatic steatosis in patients with type 2 diabetes
33
. Another data supported a role for low circulating adiponectin in the pathogenesis of non-alcoholic fat liver disorder
34
. Limitations must to be acknowledged. In this study, chronic sleep deprivation was evaluated only by questionnaires and objective sleep measures were not recorded. Nonetheless, the strength of the present study is that it is the first to examine adiponectin levels in relation to sleep deprivation in patients with multiple endocrine-metabolic disorders.
In summary, we show that chronic sleep deprivation affects approximately 1/4 of patients with endocrine-metabolic disorders. Patients with type 2 diabetes tended to have more chronic sleep deprivation. Adiponectin levels increased with age and higher values were independently associated with chronic sleep deprivation. Increased sagittal abdominal diameter and fasting insulin levels were negatively correlated with adiponectin levels. These findings reinforce the concept that low adiponectin levels have an obnoxious effect, and multiple factors and counter-regulatory effects may influence adiponectin levels. 
